A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate (PDC) in patients with FAP-positive solid tumors

Chris Twelves¹, Udai Banerji², William D. Tap³, Natalie Cook⁴, T.R.J. Evans⁵, Ruth Plummer⁶, Alan Anthoney¹, Christopher Mills¹⁰, Curtis Rink¹¹, Ruairidh Edwards¹¹, Gilad Gordon¹¹, Lee D.Cranmer¹² ¹University of Leeds and St. James's University Hospital, Leeds, ²The Institute of Cancer Research and Royal Marsden Hospital, Sutton, ³Memorial Sloan Kettering Cancer Center, New York, ⁴The Christie NHS Foundation Trust, Manchester, ⁵University, Newcastle University, Newcastle Upon Tyne, ⁷University of Bradford, Bradford, Bradford, Pharmacology, thinkQ2 AG, Baar, ⁹Octa Consulting Services Ltd, London, ¹⁰Concept Life Sciences, Edinburgh, ¹¹Avacta Life Sciences, London, ¹²University of Washington, Seattle

BACKGROUND AND PRECLINICAL DATA


MECHANISM OF ACTION OF AVA6000

Fibroblast activation protein- α (FAP) is an extracellular post-proline protease that is upregulated in many solid tumors in a membrane-bound form on cancer associated fibroblasts as well as tumor cells. FAP activity is only observed to a low degree in plasma

AVA6000 is a **peptide drug conjugate**, that leverages the tumor-specific expression of FAP by linking a peptide moiety that is specifically cleaved by FAP to doxorubicin

The **peptide moiety linker** (pre | CISION[™]) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin to tumors

FIGURE 1.



CLINICAL TRIAL METHODS

AVA6000 was assessed in a multicenter, ascending dose first-inhuman Phase 1 trial in patients. The patient population included the following:

- Patients with a diagnosis of known FAP-positive cancers, including sarcoma, pancreatic cancer, colorectal cancer, head and neck cancers. Indications previously described as FAP low were not enrolled in the trial
- Acceptable performance status (ECOG 0 or 1), adequate organ function and recovery from effects of prior therapies (with a cap on prior anthracycline)

Classification of indications as FAP high and FAP mid was based on literature. In general:

- FAP low are indications in which most patients were negative for FAP expression by IHC and/or FAPI-PET (and patients with these diseases were excluded from the trial)
- FAP mid are diseases in which some patients had reports of FAP expression FAP high are diseases in which patients
- were noted to have extensive FAP expression based on IHC and/or FAPI-PET imaging (Ballal 2021, Kratochwil 2019, Koerber 2021)

Data Cutoff 19 August 2024

BASELINE CHARACTERISTICS

TABLE 1. DEMOGRAPHICS AND BASELINE CANCER HISTORY

	AVA6000 (Q3W/Q2W) N=57		AVA6000 (Q3W/Q2W N=57
Age, median (range)	63 (30-81)	Cancer diagnosis	
Sex, m/f, n (%)	34 / 23 (59.6/40.4)	Soft tissue sarcoma (other subtype), n (%)	13 (22.8)
SEX, 11/1, 11 (70)	54725 (59.0/40.4)	Colorectal carcinoma, n (%)	11 (19.3)
ECOG, 0/1. n (%)	20 / 37 (35.1/64.9)	Salivary gland cancer, n (%)	10 (17.5)
Race		Pancreatic ducal adenocarcinoma, n (%)	8 (14.3)
M/hita = n/0(1)		Liposarcoma, n (%)	5 (8.8)
White, n (%)	47 (82.5)	Cancers of the biliary tract, n (%)	3 (7.1)
Asian, n (%)	5 (8.8)	Undifferentiated pleomorphic sarcoma, n (%)	1 (1.8)
Black or African American, n (%)	1 (1.8)	Other ¹ , n (%)	6 (10.5) ¹
	4 (5.2)	Prior systemic cancer therapy	
Not reported/unknown, n (%)	4 (5.3)	No. prior regimens, median (range)	2 (0-7)
Ethnicity		Any cytotoxic exposure, n (%)	37 (64.9)
Hispanic/Latino, n (%)	0	Anthracycline exposure, n (%)	3 (5.3)
Negligeopic per lating p (0()	F 4 (0 4 7)	Platinum exposure, n (%)	27 (47.3)
Non-Hispanic, non-Latino, n (%)	54 (94.7)	Topoisomerase l inhibitor exposure, n (%)	20 (35.1)
Not reported/unknown, n (%)	3 (5.3)	lmmunotherapy exposure, n (%)	16 (28.1)


¹ Cancer types in Other category include (n=1 each): non-small cell lung cancer, prostate cancer, transitional cell cancer of the urethra, ovarian carcinoma, lung cancer (not otherwise specified), esophageal cancer

On-treatment biopsies were obtained (n=13) at 24 hours after the dose was administered and assessed for the level of free doxorubicin in the TME by LC/MS and for FAP activity by in vitro fluorescent labeled peptide (D-Ala-Pro) assay. Plasma samples were obtained in parallel to assess the plasma concentration of doxorubicin Expression of FAP, CD31 and pan-cytokeratin were assessed based on standard immunohistochemistry (IHC, semiquantitative analysis of FAP DAB staining with hematoxylin counterstain) and multiplex immunofluorescence (IMF, quantitative analysis). Malignant and stromal compartments within the tumor were analyzed separately by IMF. Representative 4X-20X images are shown

FIGURE 2. ANALYSIS SETS

_					
SAFETY	Patients treated with at least one dose of AVA6000 (n=57) across two dose regimen arms, every 3 weeks, Q3W and every 2 weeks, Q2W. AE graded per CTCAEv5.0				
EFFICACY	Patients with: (1) known FAP higher tumor types (within the FAP+ tumor types) including soft tissue sarcoma and salivary gland cancer, (n=28) or	EVALUABLE FOR EFFICACY ANALYSIS Subset 1: 23			
	(2) FAP mid tumor types which have some evidence of FAP expression, including colorectal cancers, pancreatic cancers, etc. (n=29)	Subset 2: 26			

FIGURE 3. AVA6000 PHASE 1 TRIAL DESIGN



RESULTS

TABLE 2. TREATMENT-EMERGENT (TE) GRADE 3-4 AVA6000-RELATED HEMATOLOGIC AE COMPARED WITH **CONVENTIONAL DOXORUBICIN**

	Arm 1: Q3W dosing						Arm 2; Q2W dosing				Doxorubicin	
CTCAE Gr 3-4 Adverse events	80 mg/m ² Q3W n (%) N=4	120 mg/m ² Q3W n (%) N=6	160 mg/m² Q3W n (%) N=8	200 mg/m ² Q3W n (%) N=7	250 mg/m ² Q3W n (%) N=9	310 mg/m² Q3W n (%) N=6	385 mg/m² Q3W n (%) N=4	160 mg/m ² Q2W n (%) N=4	200 mg/m ² Q2W n (%) N=6	250 mg/m² Q2W n (%) N=3	Total n (%) N=57	(75 mg/m ² Q3W) N= 249 Gr 3-4 ¹ n (%)
Neutropenia	0	0	0	2 (29)	2 (22)	1 (17)	2 (50)	0	0	1 (33)	8 (14)	122 (49)
Leukopenia	0	0	0	1 (14)	0	1 (17)	2 (50)	0	0	0	4 (7)	59 (23.7)
Febrile neutropenia	0	0	0	0	0	0	0	0	0	0	0	41 (16.5)
Anemia	0	0	0	1 (14)	0	2 (33)	0	0	0	0	3 (5.3)	31 (12.4)
Thrombocytopenia	0	0	0	1 (14)	1 (11)	0	0	0	1 (17)	0	3 (5.3)	21 (8.4)

DOXORUBICIN

Mucositis

stomatitis

Decrease

\ppetite

FIGURE 4. COMPARISON OF SELECT TREATMENT-

Data cutoff 19 AUG 2024. ¹Tap, WD et al. 2020. JAMA 323:1266. Phase 3 trial of olaratumumab with

doxorubicin in patients with STS, (mixed 1L/2L population)

Q2W AND Q3W PHASE 1 ARMS WITH CONVENTIONAL

Doxorubicin

′5 mg/m²

EMERGENT TOXICITIES OF ANY GRADE IN THE

Q2W (160-250 mg/m², n=13)

Q3W (80-385 mg/m², n=44)

Data cutoff 19 AUG 2024. ¹Tap, WD et al. 2020. Phase 3 trial of olaratumumab with doxorubicin in patients with STS. Data reported from doxorubicin monotherapy arm, Grade 3-4 events **TABLE 3. LVEF CHANGES FROM BASELINE VS. CONVENTIONAL DOXORUBICIN**

Observed LVEF Changes from Baseline	AVA6000 80-385 mg/m ² Q3W/Q2W N=57 n (%)	Doxorubicin ¹ 75 mg/m ² Q3W N= 401 n (%)
LVEF, n (%)		
<50%	1 (1.8)	48 (12.0)
>10% decrease from baseline	7 (12.3)	191 (47.6)
<50% and/or >10% decrease from baseline	7 (12.3)	194 (48.4)

Data cutoff 19 AUG 2024 ¹Jones et al. Clin Ca Res (2021). Phase 3 ANNOUCE trial cardiac data analysis based on Tap, WD et al. 2020.

TABLE 4. DOSE-LIMITING TOXICITIES

Dose level	Event	Outcome				
120 mg/m ² Q3W	Grade 2 cardiac failure ¹	Cohort expanded and dose escalated to 160 mg/m ²				
200 mg/m ² Q3W	Grade 4 neutropenia/ thrombocytopenia	Cohort expanded and dose escalated to 250 mg/m ²				
Data cutoff 19 AUG 2024 ¹ Grade 2 cardiac failure associated with LVEF reduction from 61% (baseline) to 39% (post-C1)						

SAFETY KEY FINDINGS

- Favorable safety profile was observed in both the Q2W and Q3W dosing arms, with no MTD identified in either arm
- Limited cardiac signal with low incidence of LVEF changes and no CTCAE grade 3 or 4 severe cardiac events reported in the trial







FIGURE 6. BEST RESPONSE IN PATIENTS IN THE FAP MID EFFICACY SET



CASE STUDIES


Case Study 1

- histology)
- Prior therapy: triptorelin/ bicalutamide followed by disease progression
- first scan (SLD -22%);
- ongoing in follow-up



Case Study 2:

- in Dec 2023



Case Study 3:

- therapies
- **Q3W cohort** (Nov 2023)

REFERENCES

10.1001/jama.2020.1707 10.1002/cam4.2728


FPN: 64

79 yo male with SGC (ducta


• Enrolled in the AVA6000 trial (Oct 2023) in the **385 mg/m² Q3W cohort**; noted to have the highest

level of intratumoral doxorubicin of any patient at 24 hours post-Partial response at 12 weeks,

following minor response noted at duration of response >18 weeks Discontinued after reaching lifetime max of doxorubicin exposure; the observed PR is



In the first case, tumor cells are **negative for FAP** (aqua) with prominent FAP-positive Cancer Associated Fibroblast (CAF) populations (green) observed at the tumor-stroma interface with vessels co-localized in stroma (red)



• 65 yo female with salivary gland cancer (ductal histology), diagnosed in 2018, recurrence


• Prior therapy: bicalutamide/triptorelin with progression prior to study entry • Treated with AVA6000 in the 2L setting in the **250 mg/m² Q2W cohort** (June 2024) • **Minor response** at first scan (SLD of -14.6%, week 8); this patient continuing on trial

Tumor cells are negative for FAP (aqua) with prominent FAP-positive Cancer ociated Fibroblast (CAF) populations (green) observed at the tumor-stroma

🛑 FAP (CAFs) 🛑 CD31 (blood vessels) 🔵 PanCK (cancer cells

 55 yo male with dedifferentiated liposarcoma (DDLPS), diagnosed in 2012, noted to have a rapidly growing recurrence in 2018 • Two prior lines of therapy in the metastatic setting with progression following both

 Enrolled in AVA6000 trial in the 3L setting in the 250 mg/m² Partial response (SLD –40.5%) June 2024) following a minor response (SLD of –12.5%, Feb 2024). Patient experienced new lesions at the follow-up scan



Ballal S, et al. Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [¹⁸F]F-FDG PET/CT in patients with various cancers. *Eur J Nucl Med Mol Imaging*. 2021;48(6):1915-1931. doi: 10.1007/s00259-020-05132-y

Jones, RL *et al.* Prospective evaluation of doxorubicin cardiotoxicity in patients with advanced soft tissue sarcoma in the ANNOUNCE Phase III randomized trial. *Clin Ca Res* 2021;27:3751-66. doi: 0.1158/1078-0432.CCR-20-4592 Kratochwil C, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. / Nucl Med. 2019;60(6):801-805. doi: 10.2967/jnumed.119.227967

Koerber, S.A., et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. Eur J NNMI 48, 3918-3924 (2021) Tap WD, et al. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With

Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020;323(13):1266-1276. doi:

Kontny N et al. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years, *Cancer Chemother Pharmacol* 2013;71(3):749-63. doi: 10.1007/s00280-013-2069-1 Pérez-Blanco JS et al. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma, Br J Clin Pharmacol. 2016; 82(6): 1517–1527 Villalobos VM, et al. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma. *Cancer Med.* 2020;9(3):882-893. doi:

Acknowledgements: Avacta and the investigators wish to thank the patients and their families for participation in the clinical trial and acknowledge scientific communications assistance from SlideSource and Random 42. Multiplex immunofluorescence staining/image analysis by Concept Life Sciences.

PHARMACOKINETICS/PHARMACODYNAMICS

The PK of released doxorubicin from AVA6000 demonstrates several fundamental changes compared with conventional dose doxorubicin:


- Extension of the half-life of released doxorubicin v. conventional doxorubicin up to 40-45% Approximately 40% reduction in the peripheral volume of distribution of released dox, suggesting
- a limited distribution into normal tissues of released doxorubicin v. conventional doxorubicin Reductions in plasma C_{max} across doses compared with that observed with conventional doxorubicin

TABLE 5. PHARMACOKINETICS OF AVA6000, RELEASED DOXORUBICIN AND **CONVENTIONAL DOXORUBICIN**

	AVA Peptide drug	6000 conjugate PK	AVA-6000 releas derived from p	Con	
Dose	310 mg/m² n=6	385 mg/m² n=4	310 mg/m² n=6	385 mg/m² n=4	
AUC _{0-inf} (ng*hr)/mL Geo mean, (CV%)	12710 (9.2)	12070 (110)	1613 (8.2)	2320 (15.5)	
C _{max} (ng/mL) Geo mean, (CV%)	18650 (20.1)	12410 (197)	305 (37.8)	393.9 (63.0)	
Elimination Half-life (h) Geo mean, (CV%)	0.85 (0.1)	1.36 (105)	52.9 (69.5)	52.1 (33.9)	
Peripheral Volume distribution (L)	_	_	11:	20 ²	

Data cutoff 19 AUG 2024.¹Villalobos et al. Cancer Medicine (2020)² Data on file, Population Pharmacokinetic Model of Doxorubucin from AVA6000 (Avacta internal reference) ³Kontny et al. Cancer Chemother Pharmacol (2013); Blanco et al. (2016) B/CP

FIGURE 7. RELEASED DOXORUBICIN CONCENTRATION IN THE TUMOR VERSUS TUMOR FAP PROTEASE ACTIVITY



- The level of released doxorubicin in the tumor at 24 hours post-dose does not correlate with FAP activity level in patients with FAP+ tumor types
- This suggests even a minimal amount of FAP expression is sufficient to release the warhead in the TME
- Even at the lower levels of FAP activity in the tumor, we observe levels of released doxorubicin in the tumor at 24 hours that are substantially higher than in plasma (data not shown)

CONCLUSIONS

- AVA6000 is safe and well-tolerated in both the Q3W and Q2W dosing regimens, with preliminary evidence of efficacy and early limited cardiac safety signal. No MTD was determined in the trial despite dosing up to 385 mg/m² every 3 weeks
- Multiple RECIST responses observed in patients with FAP high and doxorubicin sensitive disease at various doses and both schedules, with durable and ongoing responses
- Confirmed partial and minor responses were observed in patients with stroma-only expression of FAP [salivary gland] and FAP expression in both stroma and tumor cells [soft tissue sarcoma]
- In tumors expressing FAP, the level of positivity appears not to correlate with the level of released doxorubicin in the TME (n=9), indicating that lower levels of FAP activity are sufficient for warhead release
- pre|CISION-enabling of doxorubicin (AVA6000) results in multiple fundamental changes in the PK of released doxorubicin (compared to conventional doxorubicin administration) including:
- Extension of the plasma half-life by ~40% and
- Approximately 40-50% reduction in both C_{max} and peripheral volume of distribution
- The study continues with recommended dose for expansion (RDE) cohorts focusing on salivary gland cancer (SGC) and subsets of soft tissue sarcoma (STS)

Prof. Chris Twelves: ORCID ID: 0000-0002-1849-7153 EMAIL: c.j.twelves@leeds.ac.uk Study funded in full by Avacta Group, plc

Presented at the European Society of Medical Oncology Annual Meeting, September 14, 2024, in Barcelona, Spain

6P	
anges	

